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ANIMAL MODELS FOR GENE 
THERAPY OF GLYCOGENOSIS
Since the first human trial in 1990, gene therapy has generated great
expectations in society. After over 20 years, there are a lot of gene
therapy protocols have reached the clinical stage. In the near future,
gene therapy will be an effective alternative to pharmacological efforts,
and enable treatment of many diseases that are refractory or not
suitable for pharmacologic treatment alone. Thus, gene therapy is a
therapeutic tool that gives us virtually unlimited possibilities to develop
better and more effective therapies for previously incurable diseases.
Before applying gene therapy in humans it is necessary to do
preclinical studies. The aim of these is protect humans of toxic effects
that the studied drug may have.
An important element in preclinical studies are animal models. First,
tests are made with small animals like mice. If they are successful,
then tests are made with larger animals, like dogs. Finally, if these
studies give good results then they are passed to higher animals:
primates or humans.
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GENE THERAPY IN VIVO  EX VIVO
GLYCOGEN STORAGE DISEASES (GSD)
Clinical disorder Gene Affectation
GSD-0 GYS2 Hepatic
GSD-Ia/Ib (Von Gierke) G6PC/G6PT1 Hepatic
GSD-II/IIb (Pompe/Danon) GAA/LAMP2 Multiorgan
GSD-III (Cori-Forbes) AGL Multiorgan
GSD-IV (Andersen) GBE1 Multiorgan
GSD-V (McArdle) PYGM Muscle
GSD-VI (Hers) PYGL Hepatic
GSD-VII (Tarui) PFKM Muscle
GSD-VIII/Ixd PHKA1 Muscle
GSD-IXa1/IXa2/Ixc PHKA2/PHKG2 Hepatic
GSD-IXb PHKB Multiorgan
Lafora EPM2A Multiorgan
GSD are hereditary disorders, usually autosomal recessive,
affecting the glycogen metabolism (Figure 2). Almost all
proteins involved in the synthesis or degradation of glycogen
and its regulation have been discovered for some types of
GSD.
Depending on the organ that glycogenosis affect we have
three types of glycogenosis (Table 1).
The frequency of all types of GSD in Europe is about
1/20,000-25,000 live births. The most common, 90% of the
total, are: GSD-I, II, III and VI [2].
SKELETAL MUSCLE GSD: GSD-VII
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- To gain insight on the role of gene therapy in the field and on the
different approaches that are being studied.
- To catch up with the preclinical phases of gene therapy.
- To know glycogen storage diseases and their types.
- To know the assays with animal models in gene therapy.
Gene therapy consists in the transfer of genetic
material into cells or tissues to prevent or cure a
disease.
There are two types of approaches in gene
therapy: in vivo and ex vivo gene therapy
(Figure 1) [1].
When designing a gene therapy approach there
are some key aspects to be considered:
HEPATIC GSD: GSD-Ia
- Exercise intolerance
- Muscle weakness
- Cramping
- Mild myopathy
- Myoglobinuria
- Compensated hemolysis
- Hypoglycemia
- Hyperlactacidemia
- Growth retardation
- Hepatomegaly
- Nephromegaly
- Hyperlipidemia
- Hyperuricemia
Preclinical phases: 
animal laboratory studies
Clinical phases: 
safety, efficacy, dosage
Deficiency in the G6Pase-catalytic
unit that hydrolyses G6P into
glucose and phosphate in the
terminal step of gluconeogenesis
and glycogenolysis.
Mutations in the muscle 6-phosphofructokinase (Pfk). 
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A single administration of Ad-mG6Pase improved
the growth rate and completely corrected the
metabolic abnormalities in these mice [3].
PAS staining revealed decreased liver glycogen
(a) 11 weeks following AAV vector administration
compared with an untreated (b), affected control
liver [4].
𝑃𝑓𝑘𝑚−/− constitutes a
unique model of GSD-VII,
which will most likely be
very useful for the design
and assessment of new
therapeutic interventions
for this disease [5].
- Gene therapy represents a promising tool to cure some of those
diseases that conventional drug therapies cannot.
- The availability of animal models is key to preclinical phases.
- In GSD-Ia, adenoviral therapy produces only short term
corrections and only impacts liver expression of the gene; while
AAV-mediated therapy achieves long term correction and the
transgene arrives to both the liver and kidney.
- In GSD-VII, the availability of the murine model allows
determination of the role of such metabolic alterations in
different tissues and organs together with their interactions, and,
importantly, allows the study of GSD-VII as a systemic disorder.
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week-old G6Pase−/− mice
Obtaining transgenic mica without PFK-1 activity
Using the technique of homologous
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Figure 1: Representation of in
vivo and ex vivo gene therapy
Table 1: Types of
glycogenosis and
the organ affected
Figure 2: Localization of
each type of glycogenosis
